Women in Delaware face an increased risk of developing lung cancer after receiving chemotherapy for breast cancer, as suggested by a recent study conducted by Epic Research, a health data group based in the state. The study revealed that women who underwent chemotherapy have a 57% higher risk of developing lung cancer compared to those who received radiation treatment. Additionally, in comparison to patients who received endocrine therapy, those who underwent chemotherapy had a 171% increase in lung cancer risk, according to the findings.
The research team emphasized the importance of monitoring for the development of primary lung cancer in women previously diagnosed with breast cancer. The study, which included over two million women aged 50 to 84 who received a screening mammogram between 2010 and 2023, excluded patients with an elevated breast cancer risk due to a previous breast or lung cancer diagnosis, recent screenings within three months, or those who started mammogram screenings before the age of 50.
Despite findings that suggest a correlation between breast cancer, its treatments, and subsequent primary lung cancer, the researchers cautioned that not every woman who has had breast cancer will necessarily develop lung cancer. Dr. Marc Siegel, a clinical professor of medicine at NYU Langone Medical Center, highlighted the potential genetic risk that one cancer may pose for the development of others, along with environmental factors or toxicities from breast cancer treatments.
Dr. Jack Manley from Viz.ai, an AI-powered disease detection platform, underscored the significance of incorporating multi-modal data in predictive algorithms for improving performance. He emphasized the importance of integrating both structured and unstructured electronic health record data with conventional imaging techniques to enhance predictive capabilities. These insights are crucial for early detection and appropriate follow-up care for patients with potential indicators of lung cancer.
Artificial intelligence tools are well-suited to address challenges in identifying patients at high risk for lung cancer, particularly those with pulmonary nodules. However, effective integration of electronic health records is essential for accurately identifying and monitoring patients at the highest risk. The study sheds light on the complex relationship between breast cancer treatments and the development of secondary lung cancer, emphasizing the importance of proactive monitoring and personalized care for at-risk individuals.